… may represent a significant clinical advantage. Among NOACs, edoxaban is the last to reach
… agents, we will focus this review on drug interactions, considering edoxaban, a NOAC with …

… Edoxaban, an oral direct Xa inhibitor, may provide clinicians with an additional option in
patients … This review examines the pharmacology and clinical data of edoxaban as a therapeutic …

… Areas covered: This article reviews the key published studies on the pharmacology, clinical
efficacy and safety of edoxaban, the latest NOAC to receive approval for the AF indication. …

… , the value of edoxaban needs to be assessed. The purpose of this review is to compare
published data on the efficacy and safety of edoxaban versus warfarin for management of …

… was to evaluate the appropriateness and clinical outcomes of edoxaban use, and to
determine the role of clinical pharmacists in improving the efficacy and safety of edoxaban use. …

… manuscript reviews the pharmacokinetic and pharmacodynamic properties of edoxaban. …
to contribute significantly to the overall pharmacological activity of edoxaban in subjects with at …

… Asian population were thinner than the Western populations in general, whether the
impact of BMI on edoxaban exposure is clinically significant remained unclear from our data. …

… practice and to clarify which FXI inhibitor may be most suited for each clinical indication.
This article reviews the rationale, pharmacology, results of medium or small phase 2 studies, …

… review the basic physiology of hemostasis, pharmacology of … medications are used in the
clinical setting. The mechanism of … edoxaban remains to be the most sensitive test for edoxaban …

… mg edoxaban … edoxaban (rather than switching from warfarin at a later date) may be more
beneficial. In the subset of patients who had their edoxaban dosage halved owing to clinical …